Treatment of NASH with human mesenchymal stem cells in the immunodeficient mouse.
Nonalcoholic steatohepatitis (NASH) as a severe form of nonalcoholic liver diseases (NAFLD) is one of the prominent liver diseases worldwide. Under favoring conditions it may progress into liver cirrhosis and hepatocellular carcinoma (HCC), which in its end stage strongly requires organ transplantation. Due to the shortage of donor organs, alternative therapeutic approaches like cell therapy treatment are necessary. In this article, an auspicious method of cell therapy with hepatocytic differentiated human mesenchymal stem cells to treat NASH in an immunodeficient mouse model is presented.